Swiss medical device developer Debiotech has partnered with dialysis products and services provider Fresenius Medical Care to develop new portfolio of peritoneal dialysis (PD) technologies.

The new product platform will include dialysis machines that are lightweight and compact, allowing in dialysis at home.

Experts from both companies will work together to develop new product platform with modern technologies.

With the exception of Japan, the partnership between the companies is exclusive across the globe.

According to Debiotech, the smaller size of Fresenius’ new generation of PD machines will provide flexibility for dialysis patients when they travel and their accompanying teaching methods are intended to make it easy for patients who are new to PD to use the machines.

Debiotech president and CEO Dr Frédéric Neftel said: "This agreement represents an ideal synergy to help patients everywhere who suffer from end stage renal disease receive the most appropriate treatment at home.

"We are very proud to work together with Fresenius Medical Care’s outstanding teams in order to bring new home peritoneal dialysis products to market and offer the hope of improved quality of life for many patients around the world."

Debiotech is involved in developing drug delivery systems and artificial organs for the treatment of severe diseases such as diabetes, renal failure, cardiovascular diseases and cancer.

Fresenius Medical Care provides dialysis treatments for patients through its network of 3,402 dialysis clinics across the globe.